Novel drugs and drug combinations for treating tuberculosis

Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis

BACKGROUND People who are newly diagnosed with pulmonary tuberculosis (TB) typically receive a standard first-line treatment regimen that consists of two months of isoniazid, rifampicin, pyrazinamide, and ethambutol followed by four months of isoniazid and rifampicin. Fixed-dose combinations (FDCs) of these drugs are widely recommended. OBJECTIVES To compare the efficacy, safety, and acceptab...

Treating Tuberculosis: Time to Introduce Fixed-Dose Drug Combinations

Improvised formulation technology In the early 1990s, FDCs of antitubercular drugs were not advocated because of their relatively poor bioavailability and short shelf life. [3] With the present improved formulation technologies, the currently available FDCs are bioequivalent to single drug reference products. Moreover, the stability of these FDCs even after six months in tropical countries is w...

Novel drugs for treating angina.

KIR-HLA combinations and susceptibility to tuberculosis

Introduction: Tuberculosis (TB), caused by Mycobacterium Tuberculosis (Mtb), with more than nine million new cases and almost two million deaths in each year is a worldwide important public health problem. Generally, human immune responses prevent Mtb spread, and the infection remains in a latent state. Both, innate and adaptive immune responses are involved against TB. However, the role of the...

Docking Studies on Novel Drugs Against Drug Re- sistant Tuberculosis

he resurgence of drug resistant tuberculosis and HIV associated intractable mycobacterial infection are of serious global concern. This is due to their potential to survive dormantly in a nonreplicating state in protective intracellular niches of Macrophages, dendritic cells, epithelial cells, endothelial cells, fibrocytes, adipocytes and bone marrow stem cells. To contain this situation, new a...